IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine + IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Japanese Encephalitis
Conditions
Japanese Encephalitis
Trial Timeline
Nov 1, 2013 → Oct 1, 2015
NCT ID
NCT01981967About IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine + IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine
IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine + IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine is a approved stage product being developed by Sanofi for Japanese Encephalitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01981967. Target conditions include Japanese Encephalitis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01981967 | Approved | Completed |
Competing Products
20 competing products in Japanese Encephalitis